Four carbapenems-imipenem, meropenem, ertapenem, and doripenem (Fig. 1A) -are used to treat human infections in North America and Europe (12). These drugs differ by the nature of the side chain (R [Fig. 1B] ) and the absence (imipenem) or presence (meropenem, doripenem, and ertapenem) of a methyl group (Fig. 1A) that has been introduced into the carbapenem ring to decrease inactivation by human renal dehydropeptidase I (12). To gain insight into the effects of structural variations in the carbapenem side chains on the efficiency of Ldt fm inactivation, we compared the four aforementioned drugs and synthesized an additional carbapenem, designated ␤-32, which contains a minimal ethyl side chain (Fig. 1C) . Ldt fm was purified from recombinant Escherichia coli by affinity and size exclusion chromatographies (16). Kinetic constants of Ldt fm were determined by spectrofluorimetry and spectrophotometry (16) for the three steps of the reaction, which comprises noncovalent binding of the drug, acylation of the catalytic Cys residue, and hydrolysis of the corresponding acyl enzyme (Fig. 1D) . Replacement of the meropenem side chain by an ethyl group (meropenem versus carbapenem ␤-32) led to a 15-fold increase in the second-order rate constant k 1 for formation of the noncovalent complex ( Fig. 2A) . Thus, the bulky side chain of meropenem (Fig. 1A) impairs access of the drug to the active site. In contrast, the rate constant of the chemical step of the reaction (k inact ) was similar for meropenem and ␤-32 (1.3 and 1.9 min Ϫ1 , respectively). This observation indicates that the side chain of meropenem is nonessential for efficient acylation.
T
he last cross-linking step of peptidoglycan synthesis is catalyzed by high-molecular-weight penicillin-binding proteins (PBPs) with D,D-transpeptidase activity, which have historically been considered the lone essential targets of ␤-lactam antibiotics. However, we recently showed that carbapenems inactivate a second class of cross-linking enzymes (9) , the L,D-transpeptidases, which bypass the classical D,D-transpeptidases by forming unusual peptidoglycan cross-links and confer high-level ampicillin resistance in mutants of Enterococcus faecium selected in vitro (10) . Transpeptidases with D,D-and L,D-specificities are structurally unrelated and harbor different catalytic nucleophiles in the form of invariant Ser (14) and Cys (1, 7) residues. L,D-Transpeptidases are sporadically distributed in Gram-positive and Gram-negative bacteria and generally have nonessential roles in peptidoglycan synthesis (6, 11) , except in Mycobacterium tuberculosis (4), Mycobacterium abscessus (5) , and Clostridium difficile (13) . Carbapenems are currently being investigated as therapeutic alternatives in the treatment of extensively drug-resistant tuberculosis (3, 8, 17) , and L,D-transpeptidases are the likely targets of the drugs in M. tuberculosis (2, 4) . Here, we investigated kinetics of inhibition of a model L,D-transpeptidase from E. faecium (Ldt fm ) by different carbapenems in order to gain insight into the role of the antibiotic side chains in the efficiency of L,D-transpeptidase inactivation.
Four carbapenems-imipenem, meropenem, ertapenem, and doripenem (Fig. 1A) -are used to treat human infections in North America and Europe (12) . These drugs differ by the nature of the side chain (R [Fig. 1B] ) and the absence (imipenem) or presence (meropenem, doripenem, and ertapenem) of a methyl group (Fig. 1A ) that has been introduced into the carbapenem ring to decrease inactivation by human renal dehydropeptidase I (12) . To gain insight into the effects of structural variations in the carbapenem side chains on the efficiency of Ldt fm inactivation, we compared the four aforementioned drugs and synthesized an additional carbapenem, designated ␤-32, which contains a minimal ethyl side chain (Fig. 1C) . Ldt fm was purified from recombinant Escherichia coli by affinity and size exclusion chromatographies (16) . Kinetic constants of Ldt fm were determined by spectrofluorimetry and spectrophotometry (16) for the three steps of the reaction, which comprises noncovalent binding of the drug, acylation of the catalytic Cys residue, and hydrolysis of the corresponding acyl enzyme (Fig. 1D) . Replacement of the meropenem side chain by an ethyl group (meropenem versus carbapenem ␤-32) led to a 15-fold increase in the second-order rate constant k 1 for formation of the noncovalent complex ( Fig. 2A) . Thus, the bulky side chain of meropenem (Fig. 1A) impairs access of the drug to the active site. In contrast, the rate constant of the chemical step of the reaction (k inact ) was similar for meropenem and ␤-32 (1.3 and 1.9 min Ϫ1 , respectively). This observation indicates that the side chain of meropenem is nonessential for efficient acylation.
In order to compare the hydrolysis rates (k hydrol ) of the acyl enzymes, meropenem and ␤-32 were incubated with increasing concentrations of Ldt fm , and rupture of the ␤-lactam ring was monitored by spectrophotometry over 1,000 min (Fig. 2B ). Under the conditions used, Ldt fm was totally converted to acyl enzyme in less than 3 min, and the subsequent decrease in absorbance revealed slow enzyme turnover (Fig. 2B) . The hydrolysis rate (k hydrol ) was determined by subtracting the rate of spontaneous hydrolysis observed in the absence of enzyme. Replacing the meropenem side chain by an ethyl side chain led to a 3-fold increase in k hydrol indicating that the meropenem side chain slows acyl enzyme hydrolysis. Together, these results show that the bulky side chain of meropenem has a negative effect on drug binding but a positive effect on acyl enzyme stability.
Since kinetic analyses of Ldt fm inactivation were previously performed only with imipenem (16), we determined kinetic constants for Ldt fm inactivation of commercially available carbapenems (Fig. 3) . Imipenem was the most efficient Ldt fm inhibitor, with respect to both drug binding (k 1 ϭ 0.065 M Ϫ1 min Ϫ1 ) and acylation (k inact ϭ 4.5 min Ϫ1 ). The other carbapenems, meropenem, ertapenem, and doripenem, bound to Ldt fm less rapidly (k 1 ϭ 0.011 to 0.018 M Ϫ1 min Ϫ1 ). The rates of acylation were also lower (k inact ϭ 1.3 to 1.8 min Ϫ1 ). Thus, kinetics of Ldt fm inactivation by meropenem, ertapenem, and doripenem were very similar. This observation confirms that the carbapenem side chains do not contribute to efficient drug binding or acylation, in agreement with the aforementioned comparison of meropenem and ␤-32. The absence of a methyl group on the carbapenem ring of imipenem may account for the ca. 3-fold-higher Ldt fm acylation rate observed for this drug (k inact ϭ 4.5 min Ϫ1 ) in comparison to rates for other carbapenems (k inact ϭ 1.3 to 1.9 min Ϫ1 ). The rate constant for binding of imipenem (k 1 ϭ 0.065 M Ϫ1 min Ϫ1 ) was intermediate between that of ␤-32 (k 1 ϭ 0.17 M Ϫ1 min Ϫ1 ) and those of meropenem, ertapenem, and doripenem (k 1 ϭ 0.011 to 0.018 M Ϫ1 min Ϫ1 ). The rate constant k 1 therefore appears to be inversely correlated with the size of the side chain (Fig. 1A) .
Comparison of acyl enzyme stability (Fig. 3) indicated that the rate constant for hydrolysis was 2-to 3-fold higher for carbapenem ␤-32 (1.87 ϫ 10 Ϫ3 min Ϫ1 ) than for ertapenem, doripenem, and meropenem (0.60 to 0.91 ϫ 10 Ϫ3 min Ϫ1 ). These results confirmed that the bulky side chain of carbapenems stabilizes the acyl enzyme. Hydrolysis of imipenem by Ldt fm was undetectable (Ͻ0.37 ϫ 10 Ϫ3 min Ϫ1 ). In order to compare the antibacterial activities of carbapenems, MICs were determined for E. faecium M512, which is resistant to ampicillin due to activation of the L,D-transpeptidation pathway. M512, formerly designated D344M512 (10), was obtained by serial selection on media containing increasing concentrations of ampicillin and derives from hypersusceptible E. faecium D344S, which does not harbor the gene encoding low-affinity PBP5. MICs of carbapenems were determined in the presence of ampicillin (200 g/ml), a drug concentration which was chosen to fully inactivate the D,D-transpeptidation pathway (9) . Under such conditions, M512 relies exclusively on Ldt fm for peptidoglycan cross-linking, thereby providing an estimate of in vivo enzyme inhibition (9) . The lowest MIC (0.5 g/ml) was observed for imipenem that combines relatively high k 1 and k inact . For ␤-32, the large increase in k 1 was not associated with the expected decrease of the MIC, indicating, as expected, that acyl enzyme stability and efficient drug binding are both important for antibacterial activity of carbapenems. Together, these data show that the bulky side , and k inact were determined by spectrofluorimetry, as previously described (16) . Ldt fm (10 M) was incubated with meropenem or carbapenem ␤-32 (100 and 300 M) in sodium phosphate buffer (100 mM; pH 6.0) and fluorescence was recorded at 10°C on a Cary Eclipse spectrofluorimeter (Varian SA) equipped with a stopped-flow apparatus (RX-2000; Applied Photophysics). Trp residues were excited at 225 nm with a slit of 5 nm and an optical path length of 2 mm. Fluorescence emission was determined at 335 nm with a slit of 5 nm and an optical path length of 10 mm (gray lines). The detector voltage was set to 600 V. Fluorescence was normalized to the fluorescence intensity of free Ldt fm , which was the lone form of the enzyme at the onset of the reaction. Kinetic constants were determined by fitting simulations (dotted lines) to experimental data (gray lines), as previously described (16) . Fitting was simultaneously performed with four drug concentrations (30, 100, 300, and 1,000 M; results for only two concentrations are shown for clarity). MICs of carbapenems for E. faecium M512 were determined at 37°C in brain heart infusion broth (Difco) containing 200 g/ml of ampicillin to inactivate the D,D-transpeptidases (9) . chains of carbapenems have both positive and negative effects in preventing hydrolysis of the acyl enzyme and impairing drug binding.
